US › Healthcare

Mink Therapeutics Inc (INKT)

US · Healthcare · Biotechnology

$9.41-5.33%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-3.1M

EPS

$-0.62

EPS estimate

$-0.60

EPS came in at -0.62 against a street estimate of -0.60 — a miss of 3.3%.

Key statistics

Market cap

$52.8M

Forward P/E

0.0

P/B

11.33

Book value

$-2.75

EPS (TTM)

$-2.39

52-week high

$16.93

52-week low

$8.48

50-day MA

$11.59

200-day MA

$11.39

Beta

0.47

Analyst view

Analysts rate Mink Therapeutics Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $39.00.

Shareholding

Insiders

59.37%

Institutions

4.00%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	1.35%
DnB NOR Asset Management (Asia)	1.08%
Longbow Finance SA	0.33%
Geode Capital Management, LLC	0.31%
Citadel Advisors Llc	0.30%
BlackRock Inc	0.26%
Vanguard Fiduciary Trust Co	0.16%
UBS Group AG	0.10%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Mink Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.